Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Stadsporten City Gate AB
Mandate

Vinge advises Stadsporten City Gate AB

May 03, 2013

Vinge has advised Stadsporten City Gate AB in connection with the sale of the company’s 70.4% shareholding in Morningstar Sweden AB to Morningstar Inc. Morningstar’s service offering in Sweden includes Morningstar Direct, investment data, internet-based tools and Morningstar.se, a website containing fund information for the general public.

Since its formation in 1997, Citygate has acted as a development company concentrating on media services and the Internet. Citygate is owned by the media groups, Eskilstuna-Kuriren AB, Mediabolaget Västkusten AB, MittMedia AB, Norrköpings Tidningars Media AB, Sydsvenska Dagbladet AB, Tidnings AB Promedia i Mellansverige and Västerbottens-Kuriren AB.

Vinge’s team consisted of partner Bo Adrianzon together with associates Johan Mattsson and Filip Öhrner.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026